drugset / Trial / NCT05911022

Probiotic and Colchicine in COVID-19

NCT05911022

Completed 150 enrolled Ain Shams University
RandomizedParallel-groupSingle-blindTreatment

Summary

Probiotics and or Colchicine may be considered as an option of treatment since they have anti-viral effect anti-inflammatory and immunomodulatory effect. A total of 150 participants were were randomly assigned (1:1:1) to receive either the standard treatment protocol and colchicine or the standard treatment protocol and probiotics or the standard treatment protocol alone for two weeks. Participants followed up twice weekly by telephone.

Timeline

Start
2021-07-01
Primary completion
2022-08-30
Completion
2022-08-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Colchicine Small molecule 0.5 mg

Indications